CF
ONCE

Centaurus Financial’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Centaurus Financial’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,000
Closed -$175K – 564
2018
Q3 		$175K Sell
3,000
-575
-16% -$39.3K 0.03% 402
2018
Q2 		$296K Sell
3,575
-270
-7% -$20.8K 0.04% 426
2018
Q1 		$256K Buy
+3,845
New +$222K 0.06% 281

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Centaurus Financial's ONCE Position: Q4 2018 in Review

Centaurus Financial sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 3,000 shares — an estimated $175K sold.

Centaurus Financial first reported a position in ONCE in Q1 2018 and held it in 3 quarters. The position peaked at $296K in Q2 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Centaurus Financial reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Centaurus Financial sold 3,000 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $175K.
  • Centaurus Financial first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Centaurus Financial's Spark Therapeutics, Inc. Common Stock position peaked at $296K in Q2 2018.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Centaurus Financial's 13F filing for Q4 2018, filed 12 Feb 2019.